Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy

Blood

Volumn 123, Issue 15, 2014, Pages 2355-2366

  Hähnel, Patricia S ^a   Enders, Birgit ^a   Sasca, Daniel ^a   Roos, Wynand P ^a   Kaina, Bernd ^a   Bullinger, Lars ^b   Theobald, Matthias ^a   Kindler, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; K RAS PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NOTCH1 RECEPTOR; SHORT HAIRPIN RNA; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; DNA END JOINING REPAIR; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; GENE SILENCING; GENOTOXICITY; IMMUNOBLOTTING; LEUKEMIA CELL; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; C57BL MOUSE; COMET ASSAY; DISEASE MODEL; DNA REPAIR; DRUG EFFECT; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COMET ASSAY; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSDUCTION, GENETIC;

EID: 84901042047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-477620     Document Type: Article

References (48)

1. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308. (Pubitemid 46480970)
2. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer. 2006;94(2):318-322. (Pubitemid 43151554)
3. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113-2119. (Pubitemid 41291728)
4. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer. 2006;46(5):579-585.
5. Perentesis JP, Bhatia S, Boyle E, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 2004;18(4):685-692. (Pubitemid 38500186)
6. Stites EC, Ravichandran KS. A systems perspective of ras signaling in cancer. Clin Cancer Res. 2009;15(5):1510-1513.
7. Parsons DW, Wang T-L, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature. 2005;436(7052):792. (Pubitemid 41160630)
8. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997;57(11):2140-2143. (Pubitemid 27247028)
9. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5(4): 375-387. (Pubitemid 38482073)
10. Kindler T, Cornejo MG, Scholl C, et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood. 2008;112(8):3373-3382.
11. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12(9): 440-450. (Pubitemid 44291571)
12. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411(6835):366-374. (Pubitemid 32467046)
13. Meek K. New targets to translate DNA-PK signals. Cell Cycle. 2009;8(23):3809.
14. Meek K, Gupta S, Ramsden DA, Lees-Miller SP. The DNA-dependent protein kinase: the director at the end. Immunol Rev. 2004;200:132-141. (Pubitemid 38998198)
15. Wang J, Pluth JM, Cooper PK, Cowan MJ, Chen DJ, Yannone SM. Artemis deficiency confers a DNA double-strand break repair defect and Artemis phosphorylation status is altered by DNA damage and cell cycle progression. DNA Repair (Amst). 2005;4(5):556-570. (Pubitemid 40462044)
16. Li B, Comai L. Functional interaction between Ku and the werner syndrome protein in DNA end processing. J Biol Chem. 2000;275(37): 28349-28352.
17. Roth DB, Wilson JH. Nonhomologous recombination in mammalian cells: role for short sequence homologies in the joining reaction. Mol Cell Biol. 1986;6(12):4295-4304. (Pubitemid 17217374)
18. Roth DB, Porter TN, Wilson JH. Mechanisms of nonhomologous recombination in mammalian cells. Mol Cell Biol. 1985;5(10):2599-2607. (Pubitemid 15249545)
19. Feldmann E, Schmiemann V, Goedecke W, Reichenberger S, Pfeiffer P. DNA double-strand break repair in cell-free extracts from Ku80-deficient cells: implications for Ku serving as an alignment factor in non-homologous DNA end joining. Nucleic Acids Res. 2000;28(13): 2585-2596. (Pubitemid 30420858)
20. Wang H, Zeng ZC, Perrault AR, Cheng X, Qin W, Iliakis G. Genetic evidence for the involvement of DNA ligase IV in the DNA-PK-dependent pathway of non-homologous end joining in mammalian cells. Nucleic Acids Res. 2001;29(8):1653-1660. (Pubitemid 32427845)
21. Wang H, Rosidi B, Perrault R, et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res. 2005; 65(10):4020-4030. (Pubitemid 40775638)
22. Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170-6182. (Pubitemid 44942738)
23. Nussenzweig A, Nussenzweig MC. A backup DNA repair pathway moves to the forefront. Cell. 2007;131(2):223-225. (Pubitemid 47576147)
24. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother Oncol. 2009;92(3):310-315.
25. Wang H, Perrault AR, Takeda Y, Qin W, Wang H, Iliakis G. Biochemical evidence for Ku-independent backup pathways of NHEJ. Nucleic Acids Res. 2003;31(18):5377-5388. (Pubitemid 37441906)
26. Sallmyr A, Tomkinson AE, Rassool FV. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood. 2008; 112(4):1413-1423.
27. Fan J, Li L, Small D, Rassool F. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood. 2010;116(24):5298-5305.
28. Olive PL, Wlodek D, Banáth JP. DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res. 1991;51(17):4671-4676.
29. Chiang MY, Xu L, Shestova O, et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest. 2008;118(9):3181-3194.
30. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243-3248. (Pubitemid 34008190)
31. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-834.
32. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2003;22(56):8999-9006. (Pubitemid 38121700)
33. Abulaiti A, Fikaris AJ, Tsygankova OM, Meinkoth JL. Ras induces chromosome instability and abrogation of the DNA damage response. Cancer Res. 2006;66(21):10505-10512. (Pubitemid 44799772)
34. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858-5868. (Pubitemid 28124064)
35. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA. 2004;101(20):7624-7629. (Pubitemid 38658079)
36. Sousa FG, Matuo R, Soares DG, et al. PARPs and the DNA damage response. Carcinogenesis. 2012;33(8):1433-1440.
37. Zhang J, Wang J, Liu Y, et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood. 2009;113(6): 1304-1314.
38. Lieber MR, Grawunder U, Wu X, Yaneva M. Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Curr Opin Genet Dev. 1997;7(1):99-104. (Pubitemid 27092771)
39. Berkovich E, Ginsberg D. Ras induces elevation of E2F-1 mRNA levels. J Biol Chem. 2001; 276(46):42851-42856.
40. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res. 1995;23(23): 4836-4843.
41. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADPribose) and PARPs. Nat Rev Mol Cell Biol. 2012; 13(7):411-424.
42. Tobin LA, Robert C, Rapoport AP, et al. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene. 2013;32(14):1784-1793.
43. Tobin LA, Robert C, Nagaria P, et al. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res. 2012;10(1):96-107.
44. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009; 137(5):835-848.
45. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108- 112.
46. Azoitei N, Hoffmann CM, Ellegast JM, et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 2012;209(4):697-711.
47. Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci USA. 2012;109(8):2860-2865.
48. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293-301.